Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost;Comparaison du timolol sans conservateur et du timolol à délivrance prolongée donnés une fois par jour en association à du latanoprost

Journal Francais d'Ophtalmologie

Volumn 27, Issue 9 I, 2004, Pages 971-977

  Bron, A ^a   Velasque, L ^b   Rebica, H ^c   Pouliquen, P ^c   Elena, P P ^d   Rouland, J F ^e  

^a HÔPITAL DU BOCAGE   (France)

^b Hôpital Militaire Sainte Anne   (France)

^c Service Direction Médicale   (France)

^d Clirophtha   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic glaucoma; Latanoprost; Nonpreserved timolol; Timolol maleate gel forming solution

Indexed keywords

ANTIGLAUCOMA AGENT; LATANOPROST; TIMOLOL; TIMOLOL MALEATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYELID DISEASE; FEMALE; GEL; GLAUCOMA; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TIME; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

EID: 9344224521     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(04)96251-1     Document Type: Article

References (34)

1. Kerrigan-Baumrind LA, Quigley HA, Pease ME, Kerrigan DF, Mitchell RS. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. IOVS, 2000;41:741-8.
2. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol, 2002;120:701-3.
3. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology, 2001;108:1943-53.
4. Heijl A, Leske C, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol, 2002;120:1268-79.
5. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol, 2000;130: 429-40.
6. Maurice D, Mishima S. Pharmacology of the eye. Autonomic nervous system: adrenergic antagonists. Ed Springer-Verlag, New York, 1984: p. 249-277.
7. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2α analog, on aqueous humor dynamics in human eyes. Ophthalmology, 1993;100:1297-304.
8. Van Buskirk M. The uncertain tonometer. J Glaucoma, 2003;12:95-7.
9. Jampel HD. Target pressure in glaucoma therapy. J Glaucoma, 1997;6:133-8.
10. Van Buskirk EM. Aphorisms of the hero. J Glaucoma, 2003;12:189-92.
11. Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci, 1984;25:776-80.
12. Konstas AG, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol, 1997;115:182-5.
13. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci, 2000;4: 2566-73.
14. Noel C, Kabo AM, Romanet JP, Montmayeur A, Buguet A. Twenty-four-hour time course of intraocular pressure in healthy and glaucomatous Africans: relation to sleep patterns. Ophthalmology, 2001;108:139-44.
15. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci, 1985;26:1315-9.
16. Konstas AG, Mantziris DA, Maltezos A, Cate EA, Stewart WC. Comparison of 24 hour control with Timoptic 0.5% and Timoptic-XE 0.5% in exfoliation and primary open-angle glaucoma. Acta Ophthalmol Scand, 1999;77:541-3.
17. Rouland JF, Morel-Mandrino P, Elena PP, Polzer H, Sunder Raj P. Timolol 0.1% gel (Nyogel 0.1% once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety. Ophthalmologica, 2002;216:449-54.
18. Soil DB. Evaluation of timolol in chronic open-angle glaucoma. Once a day vs twice a day. Arch Ophthalmol, 1980;98:2178-81.
19. Letchinger SL, Frohlichstein D, Glieser DK, Higginbotham EJ, Wilensky JT, Viana MA, et al. Can the concentration of timolol or the frequency of its administration be reduced? Ophthalmology, 1993;100:1259-62.
20. Stewart WC, Leland TM, Cate EA, Stewart JA. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure. J Glaucoma, 1998;7:402-7.
21. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology, 1994;101: 454-60.
22. Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology, 1999;106:556-63.
23. Bron A, Chiambaretta F, Pouliquen P, Rigal D, Rouland JF. Intérêt de la substitution d'un traitement journalier par deux instillations de timolol par une instillation quotidienne de bêtabloquant non conservé chez des patients présentant un glaucome chronique ou une hypertonie oculaire. J Fr Ophtalmol, 2003;26:668-74.
24. Kobelt G, Jonsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol, 1998; 236:811-21.
25. Rouland JF, Le Pen C. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol, 2003;13(Suppl 4):S5-20.
26. Realini T, Fechtner RD. 56000 ways to treat glaucoma. Ophthalmology, 2002;109:1955-6.
27. Wyse TB, Talluto DM, Krupin T, Rosenberg LF, Ruderman JM. Topical prostaglandins for glaucoma therapy. J Glaucoma, 1997;6:180-7.
28. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology, 1995;102:1743-52.
29. Higginbotham EJ, Diestelhorst M, Pfeiffer N, Rouland JF, Alm A. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol, 2002;47(Suppl 1):S133-40.
30. Alm A, Widengard I, Kjellgren D, Soderstrom M, Fristrom B, Heijl A, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol, 1995;79:12-6.
31. Lee PY, Shao H, Camras CB, Podos SM. Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology, 1991;98:1079-82.
32. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol, 1994;78:899-902.
33. Diestelhorst M, Larsson LI. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol, 2004;88:199-203.
34. Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol, 1999;128:692-6.